Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB241 vs rituximab plus CHOP in untreated CD20-positive DLBCL
CTR20181465Phase 3Completed
- Sponsor
- Nanjing Yoke Biotechnology
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of GB241 in diffuse large B-cell lymphoma (DLBCL), sponsored by Nanjing Yoke Biotechnology. Started Nov 2018; status: completed.
02
Drugs
GB241
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20181465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181465.